We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
MYCOFOR (Pharmacor Pty Ltd)
Product name
MYCOFOR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
113 (255 working days
Active ingredients
mycophenolate sodium
Registration type
New generic medicine
Indication
Mycofor, Mycotex, Mycophenolic acid PCOR is indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.
Mycofor, Mycotex, Mycophenolic acid PCOR is indicated for induction and maintenance treatment of adult patients with WHO Class III, IV or V lupus nephritis.
This indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were ISN/RPS (2003) Class IV. The evidence for efficacy was based on surrogate endpoints.
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine